Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Authors:
Open Access
- 9 October 2017
- journal article
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 9 (11) , 1537-1557
Abstract
Huntington9s disease (HD) is a progressive neurodegenerative disorder characterized by motor, cognitive and psychiatric problems. Previous studies indicated that levels of brain gangliosides are lower than normal in HD models and that administration of exogenous ganglioside GM1 corrects motor dysfunction in the YAC128 mouse model of HD. In this study, we provide evidence that intraventricular administration of GM1 has profound disease‐modifying effects across HD mouse models with different genetic background. GM1 administration results in decreased levels of mutant huntingtin, the protein that causes HD, and in a wide array of beneficial effects that include changes in levels of DARPP32, ferritin, Iba1 and GFAP, modulation of dopamine and serotonin metabolism, and restoration of normal levels of glutamate, GABA, L‐Ser and D‐Ser. Treatment with GM1 slows down neurodegeneration, white matter atrophy and body weight loss in R6/2 mice. Motor functions are significantly improved in R6/2 mice and restored to normal in Q140 mice, including gait abnormalities that are often resistant to treatments. Psychiatric‐like and cognitive dysfunctions are also ameliorated by GM1 administration in Q140 and YAC128 mice. The widespread benefits of GM1 administration, at molecular, cellular and behavioural levels, indicate that this ganglioside has strong therapeutic and disease‐modifying potential in HD. Synopsis Huntington9s disease (HD) is an incurable neurodegenerative disease. Intraventricular administration of ganglioside GM1 in three different HD mouse models ameliorates huntingtin levels, brain and striatal atrophy, motor and cognitive defects and other neurochemical levels. Administration of GM1 decreases levels of toxic soluble and insoluble mutant huntingtin. GM1 slows down neurodegeneration and white matter atrophy in R6/2 mice. GM1 restores normal levels of key neurotransmitters in the brain. GM1 improves and even restores to normal motor function in HD mice, and corrects psychiatric‐like and cognitive dysfunction. GM1 could be a novel disease‐modifying therapy for HD.Keywords
Funding Information
- Huntington Society of Canada
- Canada Research Chairs
- Canadian Institutes of Health Research (MOP 111219)
- Canadian Institutes of Health Research (PDD 115217)
- Alberta Innovates - Health Solutions
This publication has 193 references indexed in Scilit:
- Effect of Tetrabenazine on Motor Function in Patients with Huntington DiseaseNeurology and Therapy, 2012
- Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin SynthesisNeuron, 2012
- Huntington's Disease and the Striatal Medium Spiny Neuron: Cell-Autonomous and Non-Cell-Autonomous Mechanisms of DiseaseNeurotherapeutics, 2012
- Thy1‐hAPPLond/Swe+ mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social functionBrain and Behavior, 2012
- Cognitive Impairment in Huntington Disease: Diagnosis and TreatmentCurrent Neurology and Neuroscience Reports, 2011
- A tale of two factors: What determines the rate of progression in Huntington's disease? A longitudinal MRI studyMovement Disorders, 2011
- Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell IdentitiesMolecular Cell, 2010
- Neurogenesis-Dependent and -Independent Effects of Fluoxetine in an Animal Model of Anxiety/DepressionNeuron, 2009
- Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's diseaseNeuroscience, 2008
- Glycolipid and ganglioside metabolism imbalances in Huntington's diseaseNeurobiology of Disease, 2007